Three integrative cases — neonatal seizures, progressive ataxia, and a CP mimic — synthesizing testing, interpretation, and treatment.
Tags: Clinical Decision-Making · Neurogenetics
Presentation. Baby M is a 3-day-old term neonate who presents with focal clonic seizures beginning on day 2 of life. Continuous EEG monitoring reveals a burst-suppression pattern — prolonged periods of near-flat voltage suppression interrupted by high-amplitude bursts of mixed epileptiform activity. This is the most severe EEG signature of a neonatal epileptic encephalopathy: the suppression reflects pathological loss of the background activity that should be present even in a sleeping neonate, and its presence (rather than the seizures alone) is what defines the encephalopathy and predicts developmental impairment.
Why this matters for the differential. Burst-suppression in a term neonate has two broad explanations that must be separated early: an acquired static insult (hypoxic-ischemic injury, stroke, infection) versus a genetic/metabolic cause. The reassuring birth history and normal MRI below push strongly toward the latter — and within the genetic causes, burst-suppression specifically points to the early-infantile developmental and epileptic encephalopathies (the Ohtahara-spectrum phenotype) rather than benign familial neonatal epilepsy.
Birth history. Reassuringly uncomplicated: spontaneous vaginal delivery at 39 weeks with APGAR scores of 8 at one minute and 9 at five minutes. Normal APGARs and absence of a sentinel event make significant perinatal hypoxic-ischemic injury unlikely — an important point, because HIE is the diagnosis most often invoked (sometimes incorrectly) for any sick seizing neonate.
Exam. Baby M demonstrates:
The distinctive features are nonspecific here. They are worth noting but do not narrow the differential the way they would in a recognizable multiple-anomaly condition — in the neonatal epilepsies the face is usually unremarkable, and a normal-appearing infant should never lower suspicion for a channelopathy.
Family history provides important clues that must not be overlooked: the mother has a mild postural hand tremor that she has never investigated, and her maternal grandmother died of 'dementia' at age 55. Holding these in mind is the discipline this case rewards — a maternal-line tremor plus early 'dementia' is a pattern, not noise, and it will matter later.
The clinical team now faces a critical testing decision — whether to order a targeted epilepsy gene panel or proceed directly to rapid trio whole exome sequencing.
Key Points
Why trio WES here. The team chooses rapid trio whole exome sequencing over a targeted epilepsy panel for a specific reason: in a critically ill neonate the speed of a confident answer changes therapy, and the trio design (proband plus both parents) lets the lab phase variants and immediately confirm de novo status. Because the great majority of severe neonatal epileptic encephalopathy is caused by de novo dominant variants, demonstrating that a variant is absent in both parents supplies PS2 — a Strong line of ACMG evidence — in the same report that finds the variant, rather than requiring a second round of parental Sanger confirmation that costs days. A panel would have been a reasonable, often cheaper alternative, but it returns a variant without parental context and is fixed to its gene list.
The key test. Rapid trio WES returns within 10 days and identifies a de novo heterozygous pathogenic variant in KCNQ2: c.740C>T, p.Ala247Val.
Mechanism — and why it predicts the drug. The variant sits in the S4 voltage-sensor domain of the Kv7.2 subunit. Kv7.2 and Kv7.3 co-assemble as heterotetramers to carry the neuronal M-current, a slow, non-inactivating potassium current that acts as a brake on repetitive firing near threshold. Most KCNQ2-DEE variants act by a dominant-negative loss-of-function mechanism: the mutant subunit still folds and incorporates into the channel but poisons the tetramer, so even one mutant allele removes far more than half of M-current. With the brake gone, neurons fire in runs — clinically, seizures. This is the mechanistic basis for treatment:
ACMG classification: Pathogenic. Reported in ClinVar as pathogenic by multiple independent submitters. The evidence codes are worth reading as a logic chain, not a checklist:
Two Strong plus a Moderate already clear the Pathogenic threshold; PM1/PP3 reinforce rather than carry the call. Note that PS3 and PP3 are partly correlated (both speak to deleteriousness), so they should be weighted thoughtfully rather than treated as fully independent.
Management. Carbamazepine is initiated as a mechanism-matched first-line agent rather than escalating broad-spectrum anticonvulsants. Seizures resolve completely within 48 hours — the kind of rapid, complete response that both treats the infant and corroborates the diagnosis.
Second diagnosis (family). The retained family-history clue now pays off. The mother's tremor and the grandmother's early 'dementia' prompt targeted FMR1 testing, revealing an FMR1 premutation of 89 CGG repeats (normal <45, gray zone 45–54, premutation 55–200, full mutation >200). The premutation — not the full mutation — is what causes FXTAS via a toxic gain-of-function of the expanded CGG-containing mRNA (RNA toxicity), explaining the mother's early tremor and the grandmother's likely FXTAS misattributed to dementia. Critically, this is mechanistically unrelated to Baby M's KCNQ2 disorder, and Baby M tests negative for an FMR1 expansion.
The teaching point is a trap to avoid: a confirmed diagnosis in the proband can anchor the team and shut down inquiry into a relative's unexplained symptoms. Here, two independent molecular diagnoses coexist in one family — and the maternal premutation carries its own counseling implications (risk of FXPOI, and risk of CGG expansion to a full mutation in future pregnancies) entirely separate from the index seizure case.
Key Points
Presentation. Alex is a 14-year-old previously healthy teenager referred to the neurogenetics clinic with an 18-month history of progressive gait unsteadiness, frequent falls, and declining school performance. His parents first noticed difficulty during football practice when he began stumbling without apparent cause. Over the following months, his handwriting deteriorated and his speech became mildly slurred. The progressive trajectory over the better part of two years is itself a discriminator: it argues against a static or acute process and toward a degenerative, often inherited, disorder.
The most informative finding is the combination of cerebellar signs with absent reflexes plus large-fiber sensory loss. Pure cerebellar disease leaves reflexes intact; areflexia here signals a coexisting sensory/peripheral neuropathy and dorsal root ganglion (posterior column) involvement. A mixed cerebellar-plus-sensory-axonal picture with areflexia in a teenager is a specific, almost fingerprint pattern. (Many of these patients also show extensor plantar responses — areflexia with upgoing toes is a classic, seemingly paradoxical combination that points hard at this diagnosis.)
Family history is significant: Alex's parents are first cousins of Pakistani origin, and his older sibling, aged 17, has recently developed similar gait difficulties. Consanguinity raises the prior probability of a rare autosomal recessive condition by making the child homozygous-by-descent for a shared ancestral allele; an affected sibling with unaffected parents fits recessive inheritance and effectively excludes a dominant or X-linked pattern.
The consanguinity plus the mixed cerebellar-sensory-areflexic phenotype now focuses the recessive ataxia differential, which must be evaluated systematically before committing to a test.
Key Points
The diagnostic pitfall. WES is ordered first, a defensible choice given the genuinely broad recessive-ataxia differential and consanguinity. It returns negative — no pathogenic or likely pathogenic variant in any ataxia gene. The decisive move is interpreting that negative correctly: a negative exome does not exclude Friedreich ataxia, because the disease is caused not by a coding point mutation but by an expanded GAA repeat in the first intron of FXN. Short-read exome sequencing both targets coding exons (often skipping deep-intronic regions) and, more fundamentally, cannot span or accurately count long, homogeneous repeat tracts — the reads are shorter than the expansion and map ambiguously. The phenotype here is too characteristic to abandon on a test that is mechanistically blind to the relevant mutation type.
The key test. Targeted FXN GAA analysis by repeat-primed PCR confirms the diagnosis: Alex is homozygous for GAA expansions of roughly 850 and 920 repeats (normal alleles <33 GAA; intermediate/premutation 34–65; pathogenic full expansions in the hundreds-to-~1000+ range). RP-PCR is the right tool because it detects and approximately sizes large expansions that standard PCR (which fails to amplify across them) and short-read sequencing miss; Southern blot or long-read sequencing are alternatives.
Mechanism — why the repeat causes the disease. The intronic GAA expansion does not change the frataxin protein sequence; it silences transcription of FXN (through heterochromatin formation/R-loop effects), so patients make too little of a normal protein. Frataxin is a mitochondrial protein essential for iron-sulfur cluster biogenesis; its deficiency impairs key respiratory-chain and aconitase enzymes and promotes oxidative stress. This loss-of-expression mechanism explains two clinical facts: longer GAA tracts cause earlier, more severe disease (more silencing), and the most vulnerable tissues are the high-energy, post-mitotic ones — dorsal root ganglia, spinocerebellar tracts, and cardiomyocytes.
Diagnosis: Friedreich ataxia, confirmed. Echocardiography reveals concentric left ventricular hypertrophy consistent with early hypertrophic cardiomyopathy. This is not incidental: cardiac, not neurological, disease is the leading cause of premature death in FRDA, which is why the murmur on the screening exam earned an echo.
Cascade testing. The 17-year-old sibling undergoes targeted FXN testing (the correct, inexpensive, mechanism-specific test — not a repeat exome). He is confirmed homozygous for the same expansion. Catching him at an earlier stage allows surveillance and treatment to begin before advanced cardiomyopathy is established, illustrating why cascade testing within a family should use the known molecular target rather than re-running a broad, blind assay.
Key Points
Presentation. Priya is a 5-year-old girl referred from the cerebral palsy clinic for genetic evaluation. She was diagnosed with spastic diplegic cerebral palsy at age 2 based on gross motor delay, lower-extremity hypertonia, and persistent toe-walking. The early CP label is understandable — these features are real and common in CP — but the diagnosis was made on a cross-sectional snapshot, and CP is fundamentally a diagnosis about trajectory. The story only becomes diagnostic when the course is observed over time.
Birth history is unremarkable: term, uncomplicated spontaneous vaginal delivery, normal APGARs, no perinatal risk factors and no evidence of hypoxic-ischemic encephalopathy. CP usually has an identifiable antenatal or perinatal risk profile; its absence here weakens (without alone excluding) an acquired static etiology and should lower the threshold to look for a mimic.
Red flags — and why each one breaks the CP definition. The referring neurologist is concerned about features inconsistent with CP:
Taken together, progression + diurnal fluctuation + normal MRI + an affected relative is not atypical CP — it is a coherent argument against CP and for a treatable genetic mimic.
Key Points
Why treat before sequencing. With diurnal fluctuation and regression, the pretest probability of DRD is high enough that the most efficient and humane next step is a therapeutic trial of low-dose levodopa/carbidopa (~1 mg/kg/day of levodopa) rather than waiting on genetics. In DRD a small dose produces a large, sustained effect because the defect is in dopamine synthesis, not in the neurons or receptors themselves — the nigrostriatal pathway is structurally intact and merely substrate-starved, so replacing the downstream product restores function. (The same trial doubles as a safety net: levodopa-responsiveness is also seen in the dopamine-synthesis enzyme deficiencies, so a robust response is meaningful even before the exact gene is known.)
Response. Within two weeks Priya shows marked improvement in lower-extremity tone and motor control; by one month she walks independently for the first time in over a year. A response this complete and durable is, in practice, near-diagnostic of DRD and contrasts sharply with the partial, dose-limited, often dyskinesia-prone response seen when levodopa is tried in Parkinson disease.
Genetic confirmation. Sequencing of GCH1 reveals a heterozygous pathogenic missense variant, c.607G>A, p.Val203Ile. GCH1 encodes GTP cyclohydrolase 1, the rate-limiting enzyme for tetrahydrobiopterin (BH4) synthesis; BH4 is the obligate cofactor for tyrosine hydroxylase, the rate-limiting step in dopamine production. A single defective allele lowers BH4 enough to throttle striatal dopamine — a dominant-negative / haploinsufficiency effect on a rate-limiting cofactor — which is why a heterozygous variant suffices to cause disease.
ACMG classification: Pathogenic, read as a chain of independent evidence:
Two Strong + one Moderate + two Supporting comfortably meet the Pathogenic threshold. The strongest, most orthogonal lines here are PS3 (biology) and PS4/PP1 (human genetic evidence) — they corroborate from different directions, which is what makes the call robust rather than circular.
Cascade testing and a counseling nuance. The brother carries the same variant and improves on levodopa, confirming his toe-walking was undiagnosed DRD. GCH1-DRD is autosomal dominant with reduced penetrance that is notably sex-biased — females are affected more often and more severely than males, so an obligate male carrier can be mildly affected or even asymptomatic. This skewed penetrance can mimic skipped generations or an apparently 'sporadic' case and is a classic counseling pitfall; family members should be assessed (and offered the levodopa trial) on the basis of carrier status, not on how striking their symptoms appear.
The big-picture lesson. A meaningful minority of children carrying an 'idiopathic CP' label have an identifiable genetic etiology, and a subset of those — DRD foremost among them — are treatable. DRD is often called one of the most rewarding diagnoses in child neurology precisely because an inexpensive, well-tolerated medication can convert lifelong disability into near-normal function. The case's enduring message is procedural: when a CP diagnosis shows progression, diurnal fluctuation, a normal MRI, or a suggestive family history, reopen the differential.
For detailed coverage of GCH1 and other genetic dystonias, see the Genetic Dystonias module.
Key Points
1. A 5-day-old neonate presents with multifocal seizures refractory to phenobarbital and levetiracetam. EEG shows burst-suppression. Brain MRI is normal. Metabolic workup is unremarkable. The team considers ordering genetic testing. What is the MOST important advantage of rapid trio WES over a singleton epilepsy gene panel in this scenario?
The key advantage of trio WES (proband + both parents) is the ability to identify de novo variants — variants present in the child but absent in both parents. In neonatal epileptic encephalopathy, the majority of causative variants arise de novo, and confirming de novo status provides strong ACMG evidence for pathogenicity (PS2, a Strong evidence criterion). A singleton gene panel can identify the same variants but cannot determine whether they are de novo without separate parental testing, which adds time and complexity. Both trio WES and gene panels can detect variants in channelopathy genes; neither can detect repeat expansions. The speed of de novo confirmation in a critically ill neonate can directly impact treatment decisions.
2. A neonate with KCNQ2 epileptic encephalopathy is started on phenobarbital, which worsens the seizures. The team switches to carbamazepine based on the genetic diagnosis, and seizures resolve within 48 hours. Which concept does this case BEST illustrate?
This exemplifies precision medicine in epilepsy: identifying the specific genetic cause (KCNQ2 channelopathy) directly guides treatment selection. KCNQ2 encephalopathy variants disrupt the M-current that normally dampens repetitive neuronal firing. Sodium channel blockers (carbamazepine, oxcarbazepine, phenytoin) are specifically effective because they reduce the hyperexcitability downstream of the M-current deficit. Phenobarbital and other GABAergic agents are often ineffective or can paradoxically worsen seizures in KCNQ2 encephalopathy. This is distinct from pharmacogenomics (which concerns drug metabolism variants) — here the genetic diagnosis determines which drug mechanism is appropriate for the specific disease pathophysiology.
3. A 16-year-old with progressive gait ataxia, absent knee reflexes, pes cavus, and scoliosis has a normal whole exome sequencing result. His echocardiogram shows concentric left ventricular hypertrophy. His parents are first cousins. The neurologist orders targeted FXN GAA repeat testing, which reveals 750 and 900 GAA repeats on the two alleles. Which therapeutic intervention has been FDA-approved for this condition?
Omaveloxolone (Skyclarys) was approved by the FDA in February 2023 as the first treatment for Friedreich ataxia in patients aged 16 and older. It works by activating the NRF2 transcription factor, which upregulates antioxidant gene expression to counteract the oxidative stress caused by frataxin deficiency in mitochondria. Clinical trials demonstrated a modest but statistically significant slowing of neurological decline as measured by the modified Friedreich Ataxia Rating Scale (mFARS). The case also reinforces that WES cannot detect the GAA trinucleotide repeat expansion responsible for ~96% of Friedreich ataxia cases — targeted repeat testing is required.
4. A 4-year-old girl diagnosed with 'spastic diplegic cerebral palsy' at age 2 has been declining functionally — she previously walked with a walker but now needs a wheelchair. Her brain MRI is normal. Her mother notes she is 'a different child in the morning versus the evening.' Before ordering any genetic testing, the treating neurologist should:
The combination of progressive motor decline (incompatible with true CP, which is non-progressive), normal brain MRI, and clear diurnal fluctuation (better in morning, worse by evening) are red flags pointing strongly to dopa-responsive dystonia (DRD/Segawa disease). A therapeutic trial of low-dose levodopa should be started immediately and should NOT be delayed while awaiting genetic testing. The dramatic and sustained response to levodopa is itself virtually diagnostic. DRD is considered one of the most rewarding diagnoses in child neurology because an inexpensive, well-tolerated medication can transform a wheelchair-dependent child into an independently walking one. Approximately 20-30% of children with idiopathic CP have an underlying genetic cause, and DRD is the quintessential treatable mimic.
5. During trio WES for a critically ill neonate, the laboratory identifies a de novo pathogenic STXBP1 variant in the infant AND separately notes that the mother carries an FMR1 premutation (85 CGG repeats). This dual finding illustrates which important principle in clinical neurogenetics?
Dual or multiple genetic findings within a single family are increasingly recognized as comprehensive genomic testing becomes standard practice, occurring in approximately 5-7% of families. In this scenario, the infant's seizures are caused by the de novo STXBP1 variant (completely independent of the mother's FMR1 status), while the mother's FMR1 premutation (55-200 CGG repeats) confers her own set of risks — fragile X-associated tremor/ataxia syndrome (FXTAS), fragile X-associated primary ovarian insufficiency (FXPOI), and risk of transmitting a full mutation expansion to future children. Each finding must be evaluated independently. The key clinical lesson is that establishing one genetic diagnosis in a family should not prevent investigation of unexplained symptoms in other family members.
6. A clinical geneticist is evaluating a child with neonatal epileptic encephalopathy. The WES report shows a de novo KCNQ2 missense variant classified as a VUS. The variant is in the S4 voltage-sensor domain, absent from gnomAD, and computational tools predict it is deleterious. What additional evidence would MOST likely upgrade this variant to Likely Pathogenic or Pathogenic?
The variant already has de novo status (PS2 — Strong), location in a critical functional domain (PM1 — Moderate), absence from population databases (PM2 — Moderate), and computational predictions of deleteriousness (PP3 — Supporting). Under ACMG criteria, this combination may reach Likely Pathogenic but could be strengthened further. Well-established functional studies (PS3 — Strong) demonstrating that the variant alters Kv7.2 channel biophysics (e.g., shifted voltage-dependence, altered conductance, disrupted M-current) would provide the additional Strong evidence needed to confidently classify the variant as Pathogenic. This highlights the interplay between clinical genomics and functional biology in variant interpretation.